Thiazolidinediones in type 2 diabetes: a cardiology perspective. - Wikidata - awgldk - TriplyDB

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

http://www.wikidata.org/entity/Q37242253

about

Identifying plausible adverse drug reactions using knowledge extracted from the literature Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients.Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice.Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial.Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice.PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury.Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization.A comparison of the effect of glitazones on serum sialic acid in patients with type 2 diabetes.

P2860

Q28650098-F6158DB0-3431-46E6-8A2E-FDF9456D7300 Q33678940-7F99983D-3142-41AB-8B85-5D258C3EAE39 Q33782620-8D8B9300-7CF5-4088-8636-7BF2F260AD93 Q33976093-9E8B7BA4-2280-4C90-B44F-7CE59F0977E8 Q36366173-281CAE92-85C4-48D1-BAAD-DE937CD1CC8B Q37281187-72C9081F-09CB-4E81-A91C-8FBF0FCDCCEB Q37361545-681DEE94-E178-41CE-8C88-88457564D612 Q37681949-CB5D1C8F-D280-4F15-8A51-AB68F2177548 Q51365672-F2B689B3-554A-4537-AEF0-E3F044D73495

P2860

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

http://www.wikidata.org/entity/Q37242253

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

@en

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

@nl

type

label

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

@en

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

@nl

prefLabel

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

@en

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

@nl

P1433

Q37242253-51851C4B-83E3-4F4A-8F09-23C8FA5DD5C7

P1476

Q37242253-EFCDF1A3-17C5-4EC7-9A4E-8F9222B78D0D

P2093

Q37242253-10B4FEF5-34BD-4FE0-8C32-D31E7887381E

Q37242253-39995D02-8EBF-4267-BDF9-CA6F07796D76

P2860

Q37242253-02C1E633-9DC8-4441-A016-892CF58F06B8

Q37242253-0633E930-398E-4B5A-948C-4771F54839CF

Q37242253-0C917C04-1B50-4E5C-8C8A-31F3726453F2

Q37242253-12481FC4-3B40-4000-868A-0F2D759C783D

Q37242253-126D50BD-88C0-4EF1-9226-26123D576D71

Q37242253-14DF9888-F900-448C-B76E-E95B51C9AC48

Q37242253-15C93B1D-FB87-4E29-A719-A4E247708EF1

Q37242253-18E4A08B-BF95-4093-B153-1C642F324CA0

Q37242253-1E246671-9E57-42F9-8F19-A76A65B3B591

Q37242253-2152D319-1F62-4D96-B808-D3023AAF2449

P304

Q37242253-FB493E57-3897-4934-B2E9-A1D271603399

P31

Q37242253-307EE9F6-6500-40B1-8C17-21CB0A09CA12

Q37242253-388b9fa5-dc3e-4e5f-8e57-b7d4bb86b902

P356

Q37242253-F4BE62D8-D967-4A9E-B761-8C1EDAC022F1

P407

Q37242253-5D124041-06B0-492C-A4B8-EDADB0FD9018

P433

Q37242253-B0594D46-8FE7-4160-845B-1ABD9A1B3208

P478

Q37242253-D507F670-98B0-49A0-B7B1-CA80E3A61ACE

P50

Q37242253-D56E4EC6-8B52-431B-8C02-D8C9E1095E23

P577

Q37242253-C3499C71-161A-49BA-865E-7DF11062EB29

P698

Q37242253-C8433658-74A1-438B-B668-E6ED3569C279

P921

Q37242253-EECCAC2E-A232-4FA0-8579-54137234ABCA

P356

P1433

Annals of Pharmacotherapy

P1476

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

@en

P2093

Kim A Eagle

http://www.w3.org/2001/XMLSchema#string

Ujjaini Khanderia

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.

Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes.

Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.

P304

1466-1474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1K666

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Rodica Pop-Busui

P577

2008-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18698014

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes